查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668129

威爾姆斯腫瘤治療市場 - 全球行業規模、佔有率、趨勢、機會和預測，按類型、按治療、按最終用戶、按地區和競爭進行細分，2020-2030 年預測

Wilms Tumor Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By End User By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 Wilms 腫瘤治療市場價值為 15.5 億美元，預計在預測期內將穩步成長，到 2030 年的年複合成長率(CAGR) 為 4.60%。威爾姆斯腫瘤，也稱為腎母細胞瘤，是一種罕見的兒童腎癌，主要影響 3 至 4 歲的兒童。

市場概況
預測期 2026-2030
2024 年市場規模 15.5 億美元
2030 年市場規模 20.3 億美元
2025-2030 年複合年成長率 4.60％
成長最快的領域 良好的組織學
最大的市場 北美洲

推動市場成長的主要因素之一是全球威爾姆斯腫瘤發生率的上升。儘管被歸類為罕見，它仍然是兒童中最常見的腎癌類型之一。早期診斷和醫學影像技術的進步提高了檢測率，進一步增加了對有效治療的需求。手術，特別是腎臟切除術（切除受影響的腎臟），仍然是治療的基石。然而，化療和某些情況下的放射療法對於預防復發和提​​高存活率至關重要。

製藥業在開發適合兒科患者需求的新型化療藥物和創新治療方案方面發揮關鍵作用。此外，正在進行的研究正在探索標靶治療和免疫療法，這些療法可以透過針對腫瘤生長背後的遺傳和分子因素來改變治療前景，同時最大限度地減少對健康組織的損害，從而為患者提供更好的治療效果。

全球威爾姆斯腫瘤治療市場競爭激烈，許多製藥公司、研究機構和醫療保健提供者參與臨床試驗和藥物開發。此外，學術界、工業界和監管機構之間的合作正在促進創新並推動新療法的批准。

主要市場促進因素

腎母細胞瘤發生率不斷上升

主要市場挑戰

認知有限和早期診斷

主要市場趨勢

個人化醫療和標靶治療

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：維爾姆斯腫瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 市場地圖

第 5 章：亞太地區 Wilms 腫瘤治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按類型
    • 按治療
    • 按最終用戶
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲 Wilms 腫瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美 Wilms 腫瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 8 章：南美洲 Wilms 腫瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 9 章：中東與非洲 Wilms 腫瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 12 章：全球 Wilms 腫瘤治療：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Cepham Life Sciences
  • Pfizer Inc.
  • Getwell Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Medline Industries, LP.
  • Sandoz International GmbH
  • Teva Pharmaceuticals Limited
  • Accord Healthcare Ireland Ltd.
  • Eugia US LLC
  • Fresenius Kabi AG

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 17617

The global Wilms Tumor Treatment Market was valued at USD 1.55 billion in 2024 and is expected to experience steady growth during the forecast period, with a compound annual growth rate (CAGR) of 4.60% through 2030. This market is a critical segment within the larger oncology pharmaceutical and healthcare sectors. Wilms tumor, also known as nephroblastoma, is a rare form of pediatric kidney cancer that predominantly affects children between the ages of 3 and 4. The treatment market for Wilms tumor includes various therapeutic approaches such as surgery, chemotherapy, radiation therapy, and, in some cases, targeted therapies or immunotherapies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.55 Billion
Market Size 2030USD 2.03 Billion
CAGR 2025-20304.60%
Fastest Growing SegmentFavorable Histology
Largest MarketNorth America

One of the primary factors driving market growth is the rising incidence of Wilms tumor worldwide. Despite being classified as rare, it remains one of the most prevalent types of kidney cancer in children. Advances in early diagnosis and medical imaging technologies have improved detection rates, further increasing the demand for effective treatments. Surgery, particularly nephrectomy (the removal of the affected kidney), continues to be the cornerstone of treatment. However, chemotherapy and, in certain cases, radiation therapy, are critical for preventing relapse and improving survival rates.

The pharmaceutical sector plays a key role in developing new chemotherapeutic agents and innovative treatment options tailored to the needs of pediatric patients. Furthermore, ongoing research efforts are exploring targeted therapies and immunotherapies, which could transform the treatment landscape by targeting the genetic and molecular factors underlying tumor growth while minimizing damage to healthy tissue, thus offering better outcomes for patients.

The global market for Wilms tumor treatment is marked by a competitive landscape, with numerous pharmaceutical companies, research institutions, and healthcare providers engaged in clinical trials and drug development. Additionally, partnerships between academia, industry, and regulatory bodies are fostering innovation and facilitating the approval of new treatments.

Key Market Drivers

Increasing Incidence of Wilms Tumor

The growing number of Wilms tumor cases is a major factor driving the expansion of the market. Annually, approximately 400,000 children and adolescents (ages 0-19) are diagnosed with cancer, with leukemia, brain tumors, lymphomas, neuroblastoma, and Wilms tumor among the most common types. In high-income countries, where advanced medical infrastructure and specialized oncology services are widely available, over 80% of pediatric cancer cases are successfully treated. However, in low- and middle-income countries (LMICs), where access to state-of-the-art therapies and specialized care is limited, the survival rate drops to below 30%. This stark contrast highlights the critical need for increased healthcare investments, strategic partnerships, and innovative treatment delivery models to address disparities in pediatric oncology outcomes globally. As the number of diagnosed cases continues to rise, so too does the demand for effective treatment solutions, prompting more investment in research, drug development, and healthcare infrastructure.

Key Market Challenges

Limited Awareness and Early Diagnosis

A significant challenge facing the global Wilms tumor treatment market is the lack of awareness and delayed diagnosis. The rarity of Wilms tumor and its resemblance to more common childhood ailments often leads to missed or delayed diagnoses, which can result in more advanced disease stages and poorer outcomes. Healthcare providers may not immediately consider Wilms tumor when children present with symptoms like abdominal pain or swelling, leading to potential misdiagnoses or delayed referrals to specialists. This delay can result in the progression of the cancer, necessitating more aggressive treatments and reducing the likelihood of a complete cure. Furthermore, parents and caregivers may not recognize the signs of Wilms tumor, with symptoms often being mistaken for less severe conditions. This lack of awareness contributes to delayed diagnoses and subsequent treatment initiation.

Key Market Trends

Personalized Medicine and Targeted Therapies

Personalized medicine and targeted therapies are rapidly transforming the Wilms tumor treatment landscape. Historically, treatment for Wilms tumor followed a one-size-fits-all approach. However, advancements in genetic profiling and molecular diagnostics are enabling more precise, individualized treatment strategies. By identifying the specific genetic abnormalities driving tumor growth, healthcare providers can select targeted therapies that specifically address these issues, improving treatment effectiveness and minimizing harm to healthy tissue. This precision medicine approach is revolutionizing how Wilms tumor is managed, offering new hope for improved patient outcomes.

Key Market Players

  • Cepham Life Sciences
  • Pfizer Inc.
  • Getwell Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Medline Industries, LP
  • Sandoz International GmbH
  • Teva Pharmaceuticals Limited
  • Accord Healthcare Ireland Ltd.
  • Eugia US LLC
  • Fresenius Kabi AG

Market Segmentation: The global Wilms Tumor Treatment Market is segmented as follows:

  • By Type
  • Favorable Histology
  • Anaplastic Histology
  • By Treatment
  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Other Therapies
  • By End-User
  • Hospitals
  • Cancer Research Centers
  • Academic and Research Institutions
  • Other Facilities
  • By Region
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

The market features a competitive environment, with a diverse range of key players involved in clinical trials and drug development. Additionally, collaborations between academic institutions, the pharmaceutical industry, and regulatory bodies are driving innovation and enabling the approval of new treatments.

Available Customizations

This report on the Global Wilms Tumor Treatment Market offers customization options tailored to specific business needs.

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Wilms Tumor Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Favorable Histology, Anaplastic Histology)
    • 4.2.2. By Treatment (Surgery, Chemotherapy, Radiation Therapy, Others)
    • 4.2.3. By End User (Hospitals, Cancer Research Centers, Academic and Research Institutes, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Treatment
    • 4.3.3. By End User
    • 4.3.4. By Region

5. Asia Pacific Wilms Tumor Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Treatment
    • 5.2.3. By End User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Wilms Tumor Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Treatment
        • 5.3.1.2.3. By End User
    • 5.3.2. India Wilms Tumor Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Treatment
        • 5.3.2.2.3. By End User
    • 5.3.3. Australia Wilms Tumor Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Treatment
        • 5.3.3.2.3. By End User
    • 5.3.4. Japan Wilms Tumor Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Treatment
        • 5.3.4.2.3. By End User
    • 5.3.5. South Korea Wilms Tumor Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Treatment
        • 5.3.5.2.3. By End User

6. Europe Wilms Tumor Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Wilms Tumor Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. Germany Wilms Tumor Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Spain Wilms Tumor Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By End User
    • 6.3.4. Italy Wilms Tumor Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Treatment
        • 6.3.4.2.3. By End User
    • 6.3.5. United Kingdom Wilms Tumor Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Treatment
        • 6.3.5.2.3. By End User

7. North America Wilms Tumor Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Wilms Tumor Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Wilms Tumor Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Wilms Tumor Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By End User

8. South America Wilms Tumor Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Wilms Tumor Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. Argentina Wilms Tumor Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. Colombia Wilms Tumor Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By End User

9. Middle East and Africa Wilms Tumor Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Wilms Tumor Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. Saudi Arabia Wilms Tumor Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. UAE Wilms Tumor Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Wilms Tumor Treatment: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Cepham Life Sciences
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Getwell Pharmaceuticals
  • 14.4. Amneal Pharmaceuticals LLC
  • 14.5. Medline Industries, LP.
  • 14.6. Sandoz International GmbH
  • 14.7. Teva Pharmaceuticals Limited
  • 14.8. Accord Healthcare Ireland Ltd.
  • 14.9. Eugia US LLC
  • 14.10. Fresenius Kabi AG

15. Strategic Recommendations

16. About Us & Disclaimer